![]() ![]() The Impact: Shares of ENDP fell sharply after the news was reported by Dow Jones Newswires. According to the Wall Street Journal story, the discussion was initiated by lenders after the pharmaceutical company reported a sharp drop in quarterly earnings earlier this month. The Details: Soma Biswas and Alexander Gladstone were first to report that Endo International PLC (ENDP) had started negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion in debt. 11:57:52 AM: Endo Begins Debt-Restructuring Talks With Creditors - WSJ.11:57:52 AM:*Drugmaker Faces Roughly 3,500 Lawsuits Over Opioid Sales – WSJ.11:57:52 AM:*Endo’s Debt Traded Down After Earnings Miss This Month - WSJ.11:57:52 AM:*Endo Agrees to Private Negotiations With Lenders’ Lawyers, Sources Say - WSJ.11:57:52 AM:*Endo Has Warned of Possible Bankruptcy Over Debt Load, Opioid Liabilities - WSJ.May 18, 2022, 11:57:52 AM: *Drugmaker Endo in Lender Talks on $8 Billion Debt Load, Sources Say.The story as it appeared on Dow Jones Newswires: Shares of Endo International PLC (ENDP) fell after Dow Jones was first to report that the pharmaceutical company had been holding talks with its lenders and senior bondholders about a possible debt restructuring. Twenty-One Day Return: ENDP highest at 57.7% CNCT lowest at -36.The Scoop: 11:57:52 AM ET – Drugmaker Endo in Lender Talks on $8 Billion Debt Load, Sources Say.Ten-Day Return: ENDP highest at 51.6% CNCT lowest at 21.2%.Five-Day Return: ENDP highest at 30.7% CNCT lowest at -15.8%.After moving 58% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 44% of the occasions.Įndo Pharmaceuticals (ENDP) Stock Return (Recent) Comparison With Peers.After moving 52% or more over a ten-day period, the stock rose in the next ten days on 33% of the occasions.After moving 31% or more over a five-day period, the stock rose in the next five days on 39% of the occasions.Also, Endo Pharmaceuticals Stock Return summarizes ENDP stock performance and chances of its rise or decline, among other metrics that matter.Ĭalculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data So, if this follows historical performance, it is likely that EDNP stock will fall to lower levels going forward. What To Expect From State Street Stock In Q2?.With Regulatory Issues In The Rearview Mirror, Alibaba Appears Cheap At $90.Steel Stock Return To Pre-Inflation Shock Highs? Here’s What To Expect From Intuitive Surgical’s Q2.What To Expect From American Airlines’ Q2?.See our analysis on Endo Pharmaceuticals Stock Chance of Rise for more details. This historical pattern reflects 12 out of 27, or about a 44% chance of a rise in ENDP stock over the coming month. Out of such 27 instances, only 12 of them resulted in ENDP stock rising over the subsequent one-month period (twenty-one trading days). Such a large rise is not common for ENDP stock, and it has occurred only 27 times over the last ten years. The court found Endo to be not liable.īut now that ENDP stock has seen a large rise of 58% over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a fall in ENDP stock over the next month. A California-state court has ruled in favor of Endo in the litigation filed against manufacturers of prescription-opioid medications. Furthermore, what went well for the stock was an update on its opioid litigation. The segment growth was driven by Vasostrict – used to treat diabetes insipidus – due to increased utilization driven by the spread of Covid-19 delta variant.Įndo also raised its full-year outlook with revenues now estimated to be $2.92 billion and earnings to be $2.82 on a per share and adjusted basis, compared to its prior guidance of $2.76 billion and $2.82, at mid-point of their range, respectively. The strong upbeat was led by a large 37% growth in Sterile Injectables segment. First, the company recently reported its Q3 results with revenue of $772 million, well above the consensus estimate of $670 million, and earnings of $0.80 per share was well above the $0.48 average of analyst forecasts. There are a couple of factors that fueled this growth. The stock price of Endo Pharmaceuticals (NASDAQ: ENDP)has seen a stellar 58% rise over the last month, while it is up 31% in a week. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |